lol646 download play store android

lol646 download play store android TikTok's future in the US appeared uncertain on Friday after a federal appeals court rejected a legal challenge to a law that requires the social media platform to cut ties with its China-based parent company or be banned by mid-January. A panel of three judges on the US Court of Appeals for the District of Columbia Circuit ruled unanimously that the law withstood constitutional scrutiny, rebuffing arguments from the two companies that the statute violated their rights and the rights of TikTok users in the US. The government has said it wants ByteDance, TikTok's parent company, to divest its stakes. But if it doesn't and the platform goes away, it would have a seismic impact on the lives of content creators who rely on the platform for income as well as users who use it for entertainment and connection. Here are some details on the ruling and what could happen next: What does the ruling say? In their lawsuit, TikTok and ByteDance, which is also a plaintiff in the case, had challenged the law on various fronts, arguing in part that the statute ran afoul of the First Amendment and was an unconstitutional bill of attainder that unfairly targeted the two companies. But the court sided with attorneys for the Justice Department who said that the government was attempting to address national security concerns and the way in which it chose to do so did not violate the constitution. The Justice Department has argued in court that TikTok poses a national security risk due to its connections to China. Officials say that Chinese authorities can compel ByteDance to hand over information on TikTok's US patrons or use the platform to spread, or suppress, information. However, the US hasn't publicly provided examples of that happening. The appeals court ruling, written by Judge Douglas Ginsburg, said the law was "carefully crafted to deal only with control by a foreign adversary''. The judges also rejected the claim that the statute was an unlawful bill of attainder or a taking of property in violation of the Fifth Amendment. Furthermore, Ginsburg wrote the law did not violate the First Amendment because the government is not looking to "suppress content or require a certain mix of content" on TikTok. What happens next? TikTok and ByteDance are expected to appeal the case to the Supreme Court, but it's unclear whether the court will take up the case. TikTok indicated in a statement on Friday the two companies are preparing to take their case to high court, saying the Supreme Court has "an established historical record of protecting Americans' right to free speech''. ''We expect they will do just that on this important constitutional issue," a company spokesperson said. Alan Morrison, a professor at The George Washington University Law School, said he expects the Supreme Court to take up the case because of the novelty of the issues raised in the lawsuit. If that happens, attorneys for the two companies still have to convince the court to grant them an emergency stay that will prevent the government from enforcing the January 19 divestiture deadline stipulated in the law, Morrison said. Such a move could drag out the process until the Justices make a ruling. Tiffany Cianci, a TikTok content creator who has supported the platform, said she was not shocked about the outcome of the court's ruling on Friday because lower courts typically defer to the executive branch on these types of cases. She believes the company will have a stronger case at the Supreme Court. "I believe that the next stages are more likely to produce a victory for TikTokers and for TikTok as a whole," Cianci said. What about Trump? Another wild card is President-elect Donald Trump, who tried to ban TikTok during his first term but said during the recent presidential campaign that he is now against such action. The Trump transition team has not offered details on how Trump plans to carry out his pledge to "save TikTok''. But spokeswoman Karoline Leavitt said in a statement last month that he plans to "deliver" on his campaign promises. After Trump takes office on January 20th, it would fall on his Justice Department to enforce the law and punish any potential violators. Penalties would apply to any app stores that would violate a prohibition on TikTok and to internet hosting services which would be barred from supporting it. Some have speculated that Trump could ask his Justice Department to abstain from enforcing the law. But tech companies like Apple and Google, which offer TikTok's app on their app stores, would then have to trust that the administration would not come after them for any violations. Craig Singleton, senior director of the China program at the Foundation for Defence of Democracies, said enforcement discretion — or executive orders — can not override existing law, leaving Trump with "limited room for unilateral action''. There are other things Trump could potentially do. It's possible he could invoke provisions of the law that allow the president to determine whether a sale or a similar transaction frees TikTok from "foreign adversary" control. Another option is to urge Congress to repeal the law. But that too would require support from congressional Republicans who have overwhelmingly supported the prospect of getting TikTok out of the hands of a Chinese company. In a statement issued on Friday, Republican Rep. John Moolenaar of Michigan, chairman of the House Select Committee on China, said he was "optimistic that President Trump will facilitate an American takeover of TikTok" and allow its continued use in the United States. Is anyone trying to buy TikTok? ByteDance has said it won't sell TikTok. And even if it wanted to, a sale of the proprietary algorithm that powers TikTok is likely to get blocked under Chinese export controls that the country issued in 2020. That means if TikTok is sold without the algorithm, its likely that the buyer would only purchase a shell of the platform that doesn't contain the technology that made the app a cultural powerhouse. Still, some investors, including Trump's former Treasury Secretary Steven Mnuchin and billionaire Frank McCourt, have expressed interest in buying it. This week, a spokesperson for McCourt's Project Liberty initiative, which aims to protect online privacy, said participants in their bid have made informal commitments of more than USD 20 billion in capital. The spokesperson did not disclose the identity of the participants. (This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Dallas Cowboys star guard Zack Martin is doubtful for Sunday's game against the Washington Commanders due to ankle and shoulder injuries. Martin didn't practice at all this week. He also physically struggled during Monday night's loss to the Houston Texas. Martin, who turned 34 on Wednesday, has started all 162 games played in 11 seasons with the Cowboys. He's a nine-time Pro Bowl selection and a seven-time first-team All-Pro. Tight end Jake Ferguson (concussion) and safety Markquese Bell (shoulder) have been ruled out. Neither player practiced this week after being hurt against the Texans. Cornerback DaRon Bland (foot) practiced in full this week and will make his season debut. He was injured in August. Star wideout CeeDee Lamb (back/foot) was a full practice participant on Friday and is good to go. Cornerback Trevon Diggs (groin/knee) and receiver Brandin Cooks (knee) are among six players listed as questionable. The others are offensive tackle Chuma Edoga (toe), guard Tyler Smith (ankle/knee), defensive end Marshawn Kneeland (knee) and linebacker Nick Vigil (foot). --Field Level MediaLionel Messi wins MLS MVP award, the latest trophy on a long list of honors for the Inter Miami star FORT LAUDERDALE, Fla. (AP) — Lionel Messi is the MVP of Major League Soccer for 2024. The award comes after a season where he missed 15 of Inter Miami’s 34 regular-season matches with injuries or commitments to Argentina’s national team. He still factored into a league-high 36 goals by scoring 20 and assisting on 16 others. His 2.1 goal contributions per 90 minutes played is the best by any player in any season in MLS history. MLS revealed the voting results Friday. Messi edged out Columbus Crew forward Cucho Hernández for the award, which is determined by a poll of players, club technical staff and select media members. NFL ends investigation into sexual assault allegations against Browns QB Deshaun Watson CLEVELAND (AP) — The NFL has closed an investigation into sexual assault allegations against Cleveland Browns quarterback Deshaun Watson. The league has been reviewing the case for months, trying to determine whether Watson should be punished. League spokesman Brian McCarthy said in an email that "there was insufficient evidence to support a finding of a violation of the personal conduct policy.” Watson, who served an 11-game suspension in 2022, was accused of assault by a woman in September. She was seeking more than $1 million in damage before the sides reached a confidential settlement. Watson has played in just 19 games over three seasons for the Browns. NBA returning to China for pair of Suns-Nets preseason games in 2025 The NBA is returning to China next season. The league has struck a deal to play preseason games there more than five years after the league was effectively banned for Commissioner Adam Silver not punishing Daryl Morey for tweeting support of anti-government protesters in Hong Kong. Brooklyn and Phoenix will play games in China’s gambling hub of Macao on Oct. 10, 2025, and again two days later. There are more games planned for China in 2026, a source told The Associated Press. American ski racer Lindsey Vonn is picking up speed in her comeback bid at 40 years old COPPER MOUNTAIN, Colo. (AP) — American ski racer Lindsey Vonn darted through the shadows on the speed course at Copper Mountain on a frigid morning. She was on the hill Friday as she tries to make a comeback to skiing nearly six years after her last race. Vonn plans to enter a series of lower-tier FIS downhill and super-G races this weekend at Copper Mountain, Colorado. It could be the first step toward seeing her on the World Cup circuit again. Scottie Scheffler goes on a run of birdies in the Bahamas and leads by 2 NASSAU, Bahamas (AP) — Scottie Scheffler used a big run of birdies to take a two-shot lead in the Hero World Challenge in the Bahamas. Scheffler had seven birdies on the front nine for a 29. The world No. 1 added one birdie on the back nine to lead by two over Justin Thomas and Akshay Bhatia. Scheffler found no need to apologize for only one birdie on the back nine. He says it simply was a matter of the ball being a little closer to the hole and a few more putts going in. Scheffler already has eight victories this year, including Olympic gold. Hall of Famer Randy Moss is stepping away from ESPN for an extended time to deal with health issue Hall of Fame wide receiver Randy Moss is stepping away from his ESPN analyst role for an extended time to focus on a personal health challenge, the network said in a statement. Moss revealed last week that he’s dealing with a health issue and asked fans to pray for him and his family. The 47-year-old ESPN football analyst made his announcement on Instagram from the set of the network’s “Sunday NFL Countdown” show. He directed his message to men and urged them to get checkups and bloodwork done, without specifying any particular illness. No Bevo? SEC tells Texas there's no room for its 1,700-pound longhorn at title game vs. Georgia ATLANTA (AP) — The Southeastern Conference championship game will not feature another mascot showdown. The league says there's not enough space on the sideline at Mercedes-Benz Stadium in Atlanta for No. 2 Texas to bring along its 1,700-pound longhorn Bevo XV for the game against No. 5 Georgia. The teams have two of college football’s most famous mascots. There should be enough sideline space for Georgia’s pure white English bulldog, Uga XI. Before the 2019 Sugar Bowl at the Superdome in New Orleans, Bevo XV toppled his barrier and began to charge at Uga X. Texas handlers were able to pull Bevo back before any harm. The Big Ten and SEC are set to gobble up CFP bids. That could squeeze the ACC and other leagues The Big Ten and Southeastern conferences are set to gobble up the majority of the bids to the newly expanded 12-team College Football Playoff. That could squeeze the Atlantic Coast Conference and other leagues trying to maintain their footing. ACC Commissioner Jim Phillips told The Associated Press he wants clarity on the process that put two-loss Miami behind three-loss Alabama in the latest rankings. Mountain West Conference Commissioner Gloria Nevarez said she wouldn't support future changes for guaranteed numbers of bids to power conferences. The Mountain West is set to have its champion in the playoff as a Group of Five winner. NFL's next coaching cycle will feature an impressive list of candidates: Analysis The next NFL coaching cycle will feature an impressive list of candidates ranging from proven champions to up-and-coming coordinators. Six-time Super Bowl winner Bill Belichick heads the list of recognizable names that includes 2021 AP Coach of the Year Mike Vrabel. Lions offensive coordinator Ben Johnson, Buccaneers OC Liam Cohen, Bills OC Joe Brady and Eagles OC Kellen Moore are among a lengthy list of young offensive-minded coaches who will garner plenty of interest. F1 champion Max Verstappen to become first-time father with girlfriend Kelly Piquet ABU DHABI, United Arab Emirates (AP) — Formula 1 champion Max Verstappen is set to become a father for the first time with his girlfriend Kelly Piquet. There’s racing heritage on both sides of the family. Verstappen secured his fourth F1 title last month and Kelly’s father Nelson Piquet was a three-time champion in the 1980s. Verstappen says on Instagram that "we couldn’t be happier with our little miracle.” Verstappen is aiming to win his 10th F1 race of the year at the season-ending Abu Dhabi Grand Prix on Sunday. Practice gets underway later.

TV’s Dr. Oz invested in businesses regulated by agency Trump wants him to leadChina's AIMA brand electric motorbike is now in BangladeshBOSTON--(BUSINESS WIRE)--Dec 8, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVYTM (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable clinical benefits of CASGEVY. The longest follow up for both SCD and TDT patients now extends more than 5 years, with a median of 33.2 months and 38.1 months, respectively. “These comprehensive data provide additional evidence of the benefits of eradicating transfusion requirements for people with transfusion-dependent beta thalassemia and vaso-occlusive crises for those with sickle cell disease,” said Franco Locatelli, M.D., Ph.D., Professor of Pediatrics at the Catholic University of the Sacred Heart of Rome, Director of the Department of Pediatric Hematology and Oncology at Bambino Gesù Children’s Hospital, Chair of Vertex’s TDT Program Steering Committee, and Presenting Author of the CASGEVY clinical data at ASH. “With median follow-up around three years there is strong evidence for the durability of these beneficial effects following treatment with CASGEVY.” “CASGEVY is changing the outlook for people living with sickle cell disease and beta thalassemia, with these data reinforcing the immense clinical value a durable one-time therapy can provide to patients,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. “We have a strong commitment to build on our progress in bringing CASGEVY to patients around the world.” New long-term follow-up data presented from the CASGEVY trials Vertex had seven abstracts accepted at the ASH annual meeting as outlined below: Progress in bringing CASGEVY to patients around the world CASGEVY is approved for both SCD and TDT in the U.S., the European Union, Great Britain, Canada, Switzerland, Bahrain and the Kingdom of Saudi Arabia, and Vertex plans to make submissions in the United Arab Emirates and Kuwait. More than 45 authorized treatment centers have been activated globally to support the delivery of CASGEVY, and more than 40 patients have had a first cell collection. Vertex is continuing to work with reimbursement authorities to secure sustainable access for patients. Through this work, Vertex has agreements to provide CASGEVY in multiple countries, including the U.S., England (TDT), Austria, Bahrain and the Kingdom of Saudi Arabia, and continues to make strong progress in others, including positive Health Technology Assessments (HTAs) in Canada for both diseases and advancing access negotiations for SCD patients in England. In the U.S., Vertex recently secured an industry-first, voluntary agreement with the Centers for Medicare & Medicaid Services (CMS) on a single outcomes-based arrangement available to all state Medicaid programs to ensure broad and equitable access to CASGEVY. To support this progress on patient access and growing patient demand, Vertex has received approval for a third manufacturing facility for CASGEVY with our partner Lonza. About Sickle Cell Disease (SCD) SCD is a debilitating, progressive and life-shortening disease. SCD patients report health-related quality of life scores well below the general population, and the lifetime health care costs in the U.S. of managing SCD for patients with recurrent VOCs is estimated between $4 and $6 million. SCD is an inherited blood disorder that affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or “sickled” red blood cells. The clinical hallmark of SCD is VOCs, which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires a lifetime of treatment and results in a reduced life expectancy. In the U.S., the median age of death for patients living with SCD is approximately 45 years. A cure for SCD today is a stem cell transplant from a matched donor, but this option is only available to a small fraction of patients living with SCD because of the lack of available donors. About Transfusion-Dependent Beta Thalassemia (TDT) TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and the lifetime health care costs in the U.S. of managing TDT are estimated between $5 and $5.7 million. TDT requires frequent blood transfusions and iron chelation therapy throughout a person’s life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. In the U.S., the median age of death for patients living with TDT is 37 years. Stem cell transplant from a matched donor is a curative option but is only available to a small fraction of people living with TDT because of the lack of available donors. About CASGEVYTM (exagamglogene autotemcel [exa-cel]) CASGEVYTM is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. About the CLIMB Trials The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion. U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR CASGEVY (exagamglogene autotemcel) WHAT IS CASGEVY? CASGEVY is a one-time therapy used to treat people aged 12 years and older with: • sickle cell disease (SCD) who have frequent vaso-occlusive crises or VOCs • beta thalassemia (β-thalassemia) who need regular blood transfusions CASGEVY is made specifically for each patient, using the patient’s own edited blood stem cells, and increases the production of a special type of hemoglobin called hemoglobin F (fetal hemoglobin or HbF). Having more HbF increases overall hemoglobin levels and has been shown to improve the production and function of red blood cells. This can eliminate VOCs in people with sickle cell disease and eliminate the need for regular blood transfusions in people with beta thalassemia. IMPORTANT SAFETY INFORMATION What is the most important information I should know about CASGEVY? After treatment with CASGEVY, you will have fewer blood cells for a while until CASGEVY takes hold (engrafts) into your bone marrow. This includes low levels of platelets (cells that usually help the blood to clot) and white blood cells (cells that usually fight infections). Your doctor will monitor this and give you treatment as required. The doctor will tell you when blood cell levels return to safe levels. You may experience side effects associated with other medicines administered as part of the treatment regimen for CASGEVY. Talk to your physician regarding those possible side effects. Your healthcare provider may give you other medicines to treat your side effects. How will I receive CASGEVY? Your healthcare provider will give you other medicines, including a conditioning medicine, as part of your treatment with CASGEVY. It’s important to talk to your healthcare provider about the risks and benefits of all medicines involved in your treatment. After receiving the conditioning medicine, it may not be possible for you to become pregnant or father a child. You should discuss options for fertility preservation with your healthcare provider before treatment. STEP 1: Before CASGEVY treatment, a doctor will give you mobilization medicine(s). This medicine moves blood stem cells from your bone marrow into the blood stream. The blood stem cells are then collected in a machine that separates the different blood cells (this is called apheresis). This entire process may happen more than once. Each time, it can take up to one week. During this step rescue cells are also collected and stored at the hospital. These are your existing blood stem cells and are kept untreated just in case there is a problem in the treatment process. If CASGEVY cannot be given after the conditioning medicine, or if the modified blood stem cells do not take hold (engraft) in the body, these rescue cells will be given back to you. If you are given rescue cells, you will not have any treatment benefit from CASGEVY. STEP 2: After they are collected, your blood stem cells will be sent to the manufacturing site where they are used to make CASGEVY. It may take up to 6 months from the time your cells are collected to manufacture and test CASGEVY before it is sent back to your healthcare provider. STEP 3: Shortly before your stem cell transplant, your healthcare provider will give you a conditioning medicine for a few days in hospital. This will prepare you for treatment by clearing cells from the bone marrow, so they can be replaced with the modified cells in CASGEVY. After you are given this medicine, your blood cell levels will fall to very low levels. You will stay in the hospital for this step and remain in the hospital until after the infusion with CASGEVY. STEP 4: One or more vials of CASGEVY will be given into a vein (intravenous infusion) over a short period of time. After the CASGEVY infusion, you will stay in hospital so that your healthcare provider can closely monitor your recovery. This can take 4-6 weeks, but times can vary. Your healthcare provider will decide when you can go home. What should I avoid after receiving CASGEVY? What are the possible or reasonably likely side effects of CASGEVY? The most common side effects of CASGEVY include: Your healthcare provider will test your blood to check for low levels of blood cells (including platelets and white blood cells). Tell your healthcare provider right away if you get any of the following symptoms: These are not all the possible side effects of CASGEVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of CASGEVY Talk to your healthcare provider about any health concerns. Please see full Prescribing Information including Patient Information for CASGEVY. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn , Facebook , Instagram , YouTube and X . (VRTX-GEN) Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Franco Locatelli, M.D., Ph.D. and Carmen Bozic, M.D., in this press release, and statements regarding expectations for the anticipated transformative, durable clinical benefits of CASGEVY, plans to continue working with reimbursement authorities to secure sustainable access for patients, including our expectations for progress in Canada and England, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading “Risk Factors” in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov and available through the company's website at www.vrtx.com . You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. View source version on businesswire.com : https://www.businesswire.com/news/home/20241206536804/en/ CONTACT: Vertex Pharmaceuticals Incorporated Investors: InvestorInfo@vrtx.comMedia : mediainfo@vrtx.com or International: +44 20 3204 5275 or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS SOURCE: Vertex Pharmaceuticals Incorporated Copyright Business Wire 2024. PUB: 12/08/2024 12:52 PM/DISC: 12/08/2024 12:50 PM http://www.businesswire.com/news/home/20241206536804/enWhy are we eager to shame women?

Nebraska football defeats Wisconsin 44-25, securing program’s first bowl game since 2016China's AIMA brand electric motorbike is now in Bangladesh

The contest between the two captains—Rohit Sharma and Pat Cummins—has been decisively one-sided. Cummins has now dismissed Rohit on six occasions, with four of those coming in this very series. India’s Test captain, Rohit Sharma, found himself at the center of unwanted history once again as he was dismissed for just 9 runs on Day 5 of the fourth Test against Australia at the Melbourne Cricket Ground (MCG). This marks yet another disappointing performance in what has been a torrid series for the Indian opener. His early departure came off the bowling of Australian captain Pat Cummins, who now holds a unique record—having dismissed Rohit six times in Test matches, the most by any bowler against an opposition captain in the format. A Tough Road for Rohit Sharma Rohit’s struggles have been well-documented during this Border-Gavaskar Trophy series. Despite his patient start, where he faced 40 balls in a bid to anchor India’s second innings, he once again faltered under pressure. His dismissal was a result of an ambitious flick shot off Cummins, which found the edge and was brilliantly caught by Mitchell Marsh at gully. The wicket marked yet another failure for Rohit, who has struggled to convert his starts into substantial scores. The challenges for Rohit go beyond just a poor run of form. His inability to adapt to the testing conditions in Australia has been a growing concern for both fans and experts alike. With his form continuing to dip, calls for his retirement from the longest format of the game are gaining momentum. His current series average stands at a dismal 6.20, a stark contrast to the aggressive and confident opening batter India has known in him. The Cummins Factor: A Captain’s Duel The contest between the two captains—Rohit Sharma and Pat Cummins—has been decisively one-sided. Cummins has now dismissed Rohit on six occasions, with four of those coming in this very series. This statistic speaks volumes about the dominance Cummins has had over Rohit’s game in the Australian conditions. Rohit’s struggles are compounded by the fact that he has managed just 31 runs in five innings in this series, an average that ranks among the lowest for any Indian top-order batter in an away series. The Indian captain’s poor run also contrasts sharply with the form he displayed earlier in 2024, when he scored 455 runs in a high-scoring series against England. Since then, his form has seen a steep decline, raising doubts about his place in the Test team moving forward. Australia's Dominance Australia’s strong position in this Test match is a reflection of their commanding performance throughout the series. On Day 5, they set India a challenging target of 340 runs after being bowled out for 234 in their second innings. The Australians were once in trouble at 91/6, but a resilient performance from Pat Cummins and the tailenders ensured they extended their lead. Australia’s batting depth has consistently made life difficult for the Indian bowlers, and with the series on the line, every dismissal from India seems to come under greater scrutiny. India’s star pacer Jasprit Bumrah was once again the standout performer with the ball, claiming 5 wickets for 57 runs, a performance that included trapping Nathan Lyon in the morning session to end Australia’s innings. Bumrah’s wicket haul was a significant milestone, taking him past 200 Test wickets, a remarkable achievement in his career. The Road Ahead for India With India now needing 340 runs to win, the chase looks steep. The onus will be on the remaining batsmen to stage a miracle, and India’s hopes largely rest on players like Yashasvi Jaiswal, who has shown the ability to build innings despite the mounting pressure. However, with key players like Rohit Sharma and KL Rahul failing once again, India’s prospects of securing victory in the final Test match are looking slim. The final innings of the Border-Gavaskar Trophy will go down as a pivotal moment in the career of Rohit Sharma. His inability to rise to the occasion in the face of fierce Australian bowling, particularly from Pat Cummins, has led many to question his future in Test cricket. As the series concludes, all eyes will be on whether India’s captain can regain his form and restore his reputation, or whether his time as a Test opener for India is drawing to a close. Stay informed on all the latest news , real-time breaking news updates, and follow all the important headlines in india news and world News on Zee News.

NoneUpdate on plans to convert retail unit into 7-bed HMOBoxing legend Carl Froch has suggested that Tyson Fury should exclude his father from his team as the heavyweight icon enters the final stages of his training camp for his face-off with rival Oleksandr Usyk. Fury Sr once again found himself in the spotlight for all the wrong reasons after causing a commotion at the Tommy Fury vs Darren Till launch press conference earlier this week. While both Tommy and Till initially showed respect towards each other, the atmosphere quickly soured. Security had to step in when John started squirting water at Till, sparking a brawl as both fighters tried to confront each other. However, they were kept apart and the situation was eventually defused. After his latest outburst, fans swiftly took to social media to voice their displeasure towards John. One user posted: "John Fury is an embarrassment and should not be allowed near these events, always about him!" Another commented: "John Fury needs to be banned from anything boxing related. He makes it all about himself." One individual commented: "A third posted: Can someone (Carl Froch) please shut John Fury up. The man is a clown, he shouldn't be allowed near a fight promotion," while another remarked: "Not that it would make much difference to Tommy, but John Fury should not be allowed anywhere near any of his son's pressers, training camps, and especially their corners during a fight. A fifth person stated: "John Fury should be banned from all press conferences indefinitely," while another queried: "Why isn't John Fury banned from these events?" Another user questioned: "Why isn't John Fury banned from boxing?" Speaking to Action Network, Froch has now criticised Fury Sr. "The usual pathetic childish behaviour from a grown man. Darren Till did have a lot to say and he was very vocal but at the end of the day it's not about him, it's about Darren Till and Tommy Fury so why is Big John Fury, the fighting man, getting involved? "Why the f**k is he getting involved? Has he been sacked by Tyson Fury? Did Tyson tell him to f*****g do one and now he's with Tommy Fury trying to get some of the limelight? I don't know but same old s**t. Darren Till totally wrote him off." When asked if Tyson needs to sack his father, the 47- year-old responded: "I hope so, I hope he has been told, 'stay out of it, 'I've got some business to take care of and your input is not helping me, and your promotion is getting old headbutting children at press conferences.' "That kid he headbutted (at Fury v Usyk press conference) didn't even look like he could have a shave. He might've been a young man, but he picked on the smallest person there and dropped the headbutt on him. It's not the kind of behaviour you want to see, it is bad for boxing. "At the end of the day, he is a guy who wants some attention. He's a man who has never achieved anything. "His son Tyson Fury is obviously very good, he's a top fighter and we know what he's all about. I know he just lost to Oleksandr Usyk but I don't pay attention to him. I will respond to him because it's great views and does great numbers but I'm not going to start subjects just for the case of getting some clicks for the sake of getting attention." 'The Gypsy King' is currently preparing for his blockbuster showdown with Usyk. Fury will be looking to level the scores after suffering the first defeat of his professional career to the Ukrainian back in May. Speaking to Paul Dempsey last month, Fury was asked how much time he's spending about the plan tactically for the second fight with Usyk and insisted he won't be making any changes to his team. "Not much time," he said. "I know what I've got to do, nothing drastic. People can say 'I want to change trainers or I'll blame it on me conditioning coach or I'll blame it on the cook or I'll blame it on the mouse next door.' Same team, same everything. I know what I've got to do." John Fury sparked chaos at a press conference for his son Tommy's upcoming fight against Darren Till (Image: Julian Finney/Getty Images)

Crypto Analyst Foresees Pre-Christmas Bitcoin Price SurgePrairieSky Royalty Ltd. ( TSE:PSK – Get Free Report ) shares reached a new 52-week high during trading on Thursday . The company traded as high as C$29.86 and last traded at C$29.86, with a volume of 6201 shares changing hands. The stock had previously closed at C$29.62. Analyst Upgrades and Downgrades Several brokerages recently weighed in on PSK. National Bankshares boosted their target price on shares of PrairieSky Royalty from C$33.00 to C$37.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 23rd. BMO Capital Markets boosted their price objective on shares of PrairieSky Royalty from C$33.00 to C$34.00 and gave the company a “strong-buy” rating in a research report on Tuesday, October 29th. Royal Bank of Canada upgraded shares of PrairieSky Royalty from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from C$31.00 to C$33.00 in a research report on Tuesday, September 17th. Raymond James upgraded PrairieSky Royalty to a “hold” rating in a report on Thursday, October 17th. Finally, TD Securities raised their price objective on PrairieSky Royalty from C$25.00 to C$26.00 and gave the stock a “hold” rating in a report on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of C$30.80. Check Out Our Latest Analysis on PSK PrairieSky Royalty Trading Up 1.0 % PrairieSky Royalty Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Tuesday, October 15th. Shareholders of record on Friday, September 27th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.00 dividend on an annualized basis and a yield of 3.27%. PrairieSky Royalty’s dividend payout ratio (DPR) is 104.17%. Insiders Place Their Bets In other PrairieSky Royalty news, Senior Officer Daniel James Bertram bought 7,670 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of C$28.20 per share, with a total value of C$216,290.93. 0.54% of the stock is owned by insiders. PrairieSky Royalty Company Profile ( Get Free Report ) PrairieSky Royalty Ltd., a pure-play royalty company, holds crude oil and natural gas royalty interests in Canada. It holds an interest in approximately 9.7 million acres with petroleum and/or natural gas rights, 8.5 million acres of gross overriding royalty interests, and other acreage. The company was incorporated in 2013 and is based in Calgary, Canada. Recommended Stories Receive News & Ratings for PrairieSky Royalty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PrairieSky Royalty and related companies with MarketBeat.com's FREE daily email newsletter .Domestic Tourism Market to Witness Significant Growth: Key Trends and Insights Unveiled | Valuates Reports

'Fundamental act of justice': President Biden speaks on Assad's fall in SyriaAP Business SummaryBrief at 1:08 p.m. ESTThe deliberations so far are largely at the level of White House lawyers. But Biden himself has discussed the topic with senior aides, according to two people familiar with the matter who spoke on condition of anonymity to discuss the sensitive subject. No decisions have been made, the people said, and it is possible Biden opts to do nothing at all. Pardons are historically afforded to those accused of specific crimes –- and usually to those who have already been convicted of an offense — but Biden’s team is considering issuing them for some who have not even been investigated, let alone charged. The president could, if he chose, issue blanket pardons to specific people whom Trump and his allies have threatened to punish. Or he could pardon a broad class of people — not unlike pardons issued to those convicted of federal marijuana offenses or those ensnared in the “don't ask, don't tell” military policies. Either way, he'd be using the powers of the presidency in a new way. Some worry that Trump and his allies, who have talked of enemies lists and exacting “retribution,” could launch investigations that would be reputationally and financially costly for targeted people even if they don’t result in prosecutions. The door has already been opened, given that Biden has extended a broad pardon to his son, Hunter , who was convicted and pleaded guilty in tax and gun cases. Biden explained that decision by saying he believed the prosecution of his son had been poisoned by politics. White House press secretary Karine Jean-Pierre has said Biden plans additional pardons before leaving office though she would not elaborate on the process. She repeatedly referenced “changing factors” that motivated the president to pardon his son despite promising he wouldn’t. She said Republicans have continued to try to see Hunter Biden investigated for an array of alleged offenses, a rationale that could support additional pardons for Biden aides and allies. It was two weeks ago that one of the president’s closest allies in Congress, Rep, Jim Clyburn of South Carolina, encouraged Biden to pardon his son Hunter. The morning after that conversation, Clyburn told Biden’s staff that he believed the president should also pardon those being targeted by Trump. “I was very forceful in my discussions with him about what I thought he ought to do regarding his son,” Clyburn said Friday. “But I also told them that I thought he ought to go even further, because all the noise about Jack Smith and Liz Cheney and Doctor Fauci and all of that.” Special Counsel Jack Smith has been investigating Trump for his efforts to overturn the 2020 presidential election and for accusations he hoarded classified documents at his home. Liz Cheney, a conservative Republican , was the vice chairwoman of the congressional committee investigating the Jan. 6, 2021, Capitol insurrection and campaigned for Vice President Kamala Harris. Fauci, an infectious disease expert, was instrumental in the government's response to the coronavirus. All have raised the ire of Trump. Clyburn said he told Biden’s team, only half jokingly, that because the Supreme Court has already said that the president has certain immunities, “let’s give that same immunity to Jack Smith for carrying out his duties and to, Doctor Fauci, Liz Cheney, they were carrying out their duties.” Among those mentioned publicly for possible presidential pardons, there are different sentiments on whether pardons would even be wanted. Former House Speaker Nancy Pelosi supported the president’s move to pardon his son, but has been silent on the speculation that Biden is considering additional pardons for her or others. A top Pelosi ally, Rep. Adam Schiff, the Democratic congressman who led Trump’s first impeachment, has panned the idea of pardoning Biden's allies. He says “the courts are strong enough to withstand” the worst of Trump’s threats. “I don’t think a preemptive pardon makes sense,” the incoming senator told NPR recently. “I would urge the president not to do that. I think it would seem defensive and unnecessary,” Schiff said. Democratic Rep. Jamie Raskin, who was the lead manager on Trump’s second impeachment, on the charge of inciting the Jan. 6, 2021, insurrection at the Capitol, said members of Congress already are protected by the speech and debate clause in the Constitution, which protects them prosecution for participating in their legislative duties. Raskin said figures like Mark Milley, the former chairman of the Joint Chiefs of Staff, and John Kelly , Trump's former White House chief of staff, would similarly be protected by the First Amendment. But Raskin said the question is, “Should they go through the criminal investigation and prosecution for not doing anything wrong? I think that’s why this whole issue has erupted.” Raksin added that with Trump promising to pardon hundreds of people who assaulted police officers on Jan. 6th, “I can hardly fault President Biden for exploring the use of the pardon to protect people from a fraudulent and unjust prosecution.” House Democratic Leader Hakeem Jeffries said he’s had no conversations with the White House regarding any preemptive pardons for current or former members of Congress. Associated Press Writer Kevin Freking contributed to this report.

India’s first glass bridge in the sea opens at Kanyakumari’s Thiruvalluvar statue

Joel Embiid scores 31 in return to the 76ers' starting lineup against the BullsWASHINGTON — President-elect Donald Trump on Friday offered a public show of support for Pete Hegseth, his embattled choice to lead the Defense Department, whose confirmation by the Senate is in doubt as he faces questions over allegations of excessive drinking, sexual assault and his views on women in combat. Hegseth, a former Fox News Host, Army National Guard major and combat veteran, spent much of the week on Capitol Hill trying to salvage his Cabinet nomination and privately reassure Republican senators that he is fit to lead Trump’s Pentagon. “Pete Hegseth is doing very well,” Trump posted on his social media site. “He will be a fantastic, high energy, Secretary of Defense.” The president added that “Pete is a WINNER, and there is nothing that can be done to change that!!!” The pitched nomination battle over Hegseth is emerging not only as a debate about the best person to lead the Pentagon, but an inflection point for a MAGA movement that appears to be relishing a public fight over its hardline push for a more masculine military and an end to the “woke-ism” of diversity, equity and inclusion efforts. Trump’s allies are forcefully rallying around the embattled Hegseth – the Heritage Foundation’s political arm is promising to spend $1 million to shore up his nomination – as he vows to stay in the fight, as long as the president-elect wants him to. “We’re not abandoning this nomination,” Vice-President-elect JD Vance said as he toured post-hurricane North Carolina. “Pete Hegseth is going to get his hearing before the Senate Armed Services Committee, not a sham hearing before the American media,” Vance said. He said he had spoken with GOP senators and he believes Hegseth will be confirmed. “We are completely behind him.” The effort has become a test of Trump’s clout and of how far loyalty for the president-elect goes with Republican senators who have concerns about his nominees. Two of Trump’s other choices have stepped aside as they faced intense scrutiny: former congressman Matt Gaetz , his first choice for attorney general, and Chad Chronister, a Florida sheriff who was Trump’s first choice to lead the Drug Enforcement Administration. The president’s son Donald J. Trump Jr., also made a show of support for Hegseth on Friday, part of a full-court MAGA press. “If you’re a GOP Senator who voted for Lloyd Austin, but criticize @PeteHegseth, then maybe you’re in the wrong political party!” he wrote on X. referring to President Joe Biden’s defense secretary. Thanking the president-elect for the support, Hegseth posted on social media, “Like you, we will never back down.” Hegseth has promised not to drink on the job and told lawmakers he never engaged in sexual misconduct, even as his professional views on female troops have also come under intensifying scrutiny. He said as recently as last month that women “straight up” should not serve in combat . He picked up one important endorsement from Republican Sen. Katie Britt of Alabama, whose support was seen as a potentially powerful counterweight to the cooler reception Hegseth had received from Sen. Joni Ernst , herself a former Army National Guard lieutenant colonel. “Huge. Thanks to Katie for her leadership,” Vance posted on social media. Ernst, who is also a sexual assault survivor, stopped short of an endorsement after her meeting with Hegseth this week. She said she appreciates his military service and they “had a frank and thorough conversation.” On Friday, Trump put out the statement in response to coverage saying he had lost faith in Hegseth, according to a person familiar with his thinking who was not authorized to discuss it publicly. The president-elect and his team have been pleased to see Hegseth putting up a fight and his performance this week reiterates why he was chosen, the person said. They believe he can still be confirmed. If Hegseth goes down, Trump’s team believes the defeat would empower others to spread what they cast as “vicious lies” against every candidate Trump chooses. Still, Trump’s transition team has been looking at potential replacements if Hegseth’s nomination cannot move forward, including former presidential rival Florida Gov. Ron DeSantis . DeSantis plans to attend the Army-Navy football game with Trump on Dec. 14, according to a person familiar with the Florida governor’s plans who spoke to the AP on condition of anonymity to discuss them before a public announcement. And DeSantis and Trump had spoken about the defense secretary post when they saw each other Tuesday at a memorial service for sheriff deputies in West Palm Beach, Florida, according people familiar with the matter who said Trump was interested in DeSantis for the post, and the governor was receptive. At the same time, DeSantis also is poised to select a replacement for the expected Senate vacancy to be created by Marco Rubio becoming secretary of state, and Trump’s daughter-in-law Lara Trump is seen as the preferred choice by those in Trump’s orbit. Despite a weeklong push of private Capitol Hill meetings, Hegseth is facing resistance from senators as reports have emerged about his past, including the revelation that he made a settlement payment after being accused of a sexual assault that he denies. The New Yorker cited what it described as a whistleblower report and other documents about his time leading a veterans advocacy group, Concerned Veterans for America, that alleged multiple incidents of alcohol intoxication at work events, inappropriate behavior around female staffers and financial mismanagement. The New York Times obtained an email from his mother Penelope from 2018, in which she confronted him about mistreating women after he impregnated his current wife while he was married to his second wife. She went on “Fox & Friends” this week to defend her son. Trump ally Sen. Markwayne Mullin, R-Okla., said senators are judging “Pete for who he is today.” In many ways the increasingly pitched battle resembles the political and culture wars that exploded over Trump’s pick of Brett Kavanaugh for the Supreme Court during his first term at the White House. Kavanaugh had also faced allegations of sexual assault that he strenuously denied, but Republicans rallied to his side and turned a tide of opposition into a more sympathetic view of the Supreme Court nominee as the victim of a liberal-led smear campaign. He eventually won confirmation. While Hegseth was still fighting for votes in the Senate, he did appear to make incremental progress with some Republicans who had expressed concerns about the reports of his drinking, in particular. “I’m not going to make any decision regarding Pete Hegseth’s nomination based on anonymous sources,” said Sen. Lindsey Graham, R-S.C. North Dakota Sen. Kevin Cramer said of the allegations against Hegseth, “I have no reason to doubt him any more than believe somebody else.” Still, Cramer indicated he could still change his mind. A background check “will be informative.” Sen. Mike Rounds, R-S.D., said after meeting with Hegseth that he wanted to see how he does in a hearing but “he went a long way” toward getting his support. Colvin reported from New York. Associated Press writers Darlene Superville in Fariview, N.C., Michelle L. Price in New York, Adriana Gomez Licon in Ft. Lauderdale, Florida, and Mary Clare Jalonick, Kevin Freking and Lisa Mascaro in Washington contributed to this report.What links the Black Isle Isle, Vikings and the Countess of Sutherland’s shopping list?

The veteran TV journalist Bob McNeil has died. McNeil began his career in newspapers and radio but was best known for his 20-year stint as a reporter on TV3 - a role that took him to countless countries and made him a household name in New Zealand. Colleagues paying tribute on social media this morning recalled his kindness, humour and empathy for the people he interviewed. Veteran TVNZ Pacific reporter Barbara Dreaver described him as "a damn fine journo and a gentleman", while former TV3 investigative reporter Karen Rutherford said he was "one of the kindest, most genuine journos with such great wit". Journalist David Farrier described meeting McNeil in 2020, when his old friend and mentor was already battling Alzheimer's disease. "He was the master of forming trusted relationships with pretty much anyone, loved, loved, loved stories, and using humour as a way to tell them," Farrier said. McNeil's first job out of school was at the Taranaki Daily News in New Plymouth. He trained at Palmerston North Teachers College in 1961-1962, and taught at various schools, mostly in Taranaki, until 1970. In that year he took a job at Radio Waikato in Hamilton, covering major news events such as the Springbok tour protests while working at 1ZH. In 1987 he joined radio 1ZB in Auckland. A few years later, in 1989, he was hired as a news reporter by the fledgling TV channel TV3. He soon built up a reputation among his colleagues and the public for his kindness, wit and love of a good story. He retired from journalism in 2010 at the age of 67. McNeil was born in Wellington and spent his childhood in Otago, Taranaki and Hawke's Bay. He met his wife, Jeanette, during an OE in Britain. Their three children include Seven Sharp reporter Sacha McNeil. The funeral arrangements are yet to be announced. Sign up for Ngā Pitopito Kōrero, a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

LOS ANGELES (AP) — Adrian Kempe and Quinton Byfield scored in the second period, and the Los Angeles Kings beat the Seattle Kraken 2-1 on Saturday. Read this article for free: Already have an account? To continue reading, please subscribe: * LOS ANGELES (AP) — Adrian Kempe and Quinton Byfield scored in the second period, and the Los Angeles Kings beat the Seattle Kraken 2-1 on Saturday. Read unlimited articles for free today: Already have an account? LOS ANGELES (AP) — Adrian Kempe and Quinton Byfield scored in the second period, and the Los Angeles Kings beat the Seattle Kraken 2-1 on Saturday. David Rittich made 19 saves for the Kings, who improved to 6-2-1 at home. Kempe and Byfield scored 1:44 apart in the second period. Byfield buried a sharp-angle slap shot on a power play while dropping to a knee. It was his 98th career point in 200 games. Brandon Montour got the Kraken on the board with 1:26 left in the game. He converted a long shot with Joey Daccord off for another skater, but Los Angeles held on. Daccord finished with 19 stops for Seattle. Takeaways Kraken: Jordan Eberle will miss at least three months after undergoing surgery on his pelvis. He had six goals and five assists in 17 games before he got hurt against Chicago on Nov. 14. Kings: The power play had been in a 1-for-16 rut (6.25%) over the previous six games before Byfield found the net. It was the Kings’ lone opportunity with the man-advantage. Key moment After following its 1-0 loss to Buffalo on Wednesday with a fourth straight period of extreme low-event hockey, Los Angeles created a lot more activity and offense to start the second and generate its two goals. Key stat Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. The Kings know how to close out games, improving to 9-0-1 when leading after two periods. Up next The Kraken visit Anaheim on Monday, and the Kings play at San Jose on Monday. ___ AP NHL: https://apnews.com/hub/nhl Advertisement Advertisement